About Exact Sciences Corporation - Common Stock (EXAS)
Exact Sciences is a biotechnology company focused on the development and commercialization of innovative cancer screening and diagnostic solutions. With a primary emphasis on early detection, the company aims to improve patient outcomes through advanced molecular tests, including non-invasive tests that help identify colorectal cancer and other cancers at an early stage. Exact Sciences combines sophisticated technology, rigorous scientific research, and a commitment to patient care to provide healthcare providers and patients with critical information that can lead to timely interventions and better health management. Read More
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today celebrated the passage of landmark federal legislation that establishes a pathway to enable Medicare coverage for multi-cancer early detection (MCED) tests. Nearly 70% of annual cancer cases and deaths in the U.S. occur in cancers with no recommended screening,1,2 and cancer remains the second leading cause of death in the U.S.1 By aligning public policy with scientific innovation and patient need, this legislation represents a critical step toward addressing that unmet need and expanding access to this emerging technology for millions of Medicare beneficiaries.
BALA CYNWYD, Pa., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to discuss the investigation, contact Jason Brodsky (jbrodsky@brodskysmith.com) or Marc Ackerman (mackerman@brodskysmith.com) at 855-576-4847. There is no cost or financial obligation to you.
Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced a significant milestone for its flagship Oncotype DX Breast Recurrence Score® test: more than two million breast cancer patients worldwide have now used the test to help guide treatment decisions. Backed by more than two decades of clinical evidence, the test has become a global standard-of-care by identifying patients who are – and are not – likely to benefit from chemotherapy.
In a move that has sent shockwaves through the healthcare sector, Boston Scientific (NYSE:BSX) has announced a definitive agreement to acquire Penumbra (NYSE:PEN) for approximately $14.5 billion. The deal, announced in mid-January and currently the talk of Wall Street as we move into February 2026, marks one
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting bottom-line expectations for earnings per share, the healthcare giant reported a significant revenue miss that spooked investors, driven primarily by
Abbott Laboratories (NYSE: ABT) saw its shares retreat by 5.8% in early trading on Thursday, January 22, 2026, following the release of its fourth-quarter financial results. Despite delivering an adjusted earnings per share (EPS) of $1.50—narrowly edging out the $1.49 consensus estimate—the medical device giant’
The global Mergers and Acquisitions (M&A) market staged a historic comeback in 2025, with total deal value reaching a staggering $5.1 trillion. This resurgence represents a 44% year-over-year increase, signaling a definitive end to the stagnation that plagued 2023 and 2024. As of January 19, 2026, the financial
Medical technology, infection control systems, oncology radiotherapy solutions, and diagnostics innovation remain key healthcare growth themes heading into 2026—and CS Diagnostics Corp. (OTCQB: CSDX) is positioning itself at the intersection of both.
As 2026 begins, the healthcare sector is undergoing its most profound transformation in decades. Driven by a relentless push toward "precision medicine" and the industrialization of artificial intelligence, the industry has seen a staggering 150.5% year-over-year jump in deal value. The catalyst for this explosive growth was a blockbuster
In a resounding vote of confidence for the future of multi-cancer early detection (MCED), Canaccord Genuity reiterated its "Buy" rating for GRAIL (Nasdaq: GRAL) on Tuesday, January 13, 2026, setting an ambitious price target of $105.00. The move comes as the liquid biopsy pioneer reported preliminary full-year 2025 financial
Shares of Adaptive Biotechnologies (NASDAQ: ADPT) soared on Tuesday, January 13, 2026, after the life sciences company announced preliminary fourth-quarter and full-year 2025 financial results that blew past Wall Street expectations. The report highlighted a dramatic acceleration in the adoption of its clonoSEQ diagnostic test, positioning the company as a
On January 12, 2026, the diagnostic sector witnessed a seismic shift as shares of Biodesix (Nasdaq: BDSX) surged more than 40% in early trading, following the release of preliminary full-year 2025 financial results that comfortably beat both internal guidance and Wall Street estimates. The Colorado-based lung diagnostics specialist reported a
Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets.
But the many opportunities in front of them attract significant competition, spanning from industry behemoths with seemingly infinite resources to small, nimble players with chips on their shoulders.
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution.
While their quality can sometimes justify the premium, they typically experience elevated volatility during market downturns when expectations change.
Wall Street’s bearish price targets for the stocks in this article signal serious concerns.
Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps delivering the hard truth.
Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, today announced the first clinical study results from its Oncodetect® molecular residual disease (MRD) test in breast cancer. Findings from the NSABP B-59 substudy, conducted in collaboration with the NSABP Foundation and the German Breast Group (GBG), demonstrated that the Oncodetect test strongly predicts distant recurrence following surgery in patients with early triple-negative breast cancer (TNBC)2, one of the most aggressive and difficult-to-treat breast cancer subtypes.3
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Those leading the charge have realized strong financial performance,
and over the past six months, the industry’s 13.5% return has closely followed the S&P 500.
The stocks featured in this article are seeing some big returns.
Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro developments. As such, investors are taking notice and bidding up shares.
